Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 06, 2022 16:01 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of Sapanisertib in Relapsed/Refractory NRF2 (NFE2L2)-Mutated Squamous Non-Small Cell Lung Cancer

-- Patients with tumors harboring NRF2-mutations have a poorer prognosis and no available targeted therapies -- SOUTH SAN FRANCISCO, Calif., July 06, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences,...
June 23, 2022 16:05 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of Mivavotinib in Relapsed/Refractory non-GCB (ABC) Diffuse Large B-Cell Lymphoma

-- Novel biomarker will be used to identify patients in genetically defined subgroup associated with poorer outcomes -- Study will evaluate SYK inhibitor both in patients with wild-type disease and...
June 14, 2022 12:50 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences Announces 1-for-20 Reverse Stock Split

SOUTH SAN FRANCISCO, Calif., June 14, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that it has...
May 17, 2022 07:00 ET | Source: Calithera Biosciences, Inc.

Calithera to Present at the H.C. Wainwright Global Investment Conference

SOUTH SAN FRANCISCO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan...
May 10, 2022 16:05 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights

-- Conference Call and Webcast Scheduled for 2:00 p.m. PT / 5:00 p.m. ET on Tuesday, May 10, 2022 -- SOUTH SAN FRANCISCO, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc....
May 03, 2022 16:05 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences to Report First Quarter 2022 Financial Results on Tuesday, May 10, 2022

SOUTH SAN FRANCISCO, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that the...
April 08, 2022 13:01 ET | Source: Calithera Biosciences, Inc.

Calithera Presents Data Highlighting Discovery of Novel Series of Promising Synthetic Lethal Compounds

Findings presented today at AACR Annual Meeting detail Calithera discovery of VPS4A inhibitors and their potential as a therapeutic approach in numerous solid tumor cancers VPS4A and VPS4B are gene...
March 31, 2022 16:05 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., March 31, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its...
March 30, 2022 02:00 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences, Inc. Prices $10.0 Million Underwritten Public Offering of Common Stock and Warrants to Purchase Common Stock

SOUTH SAN FRANCISCO, Calif., March 30, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced the...
March 29, 2022 16:01 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences, Inc. Announces Commencement of Underwritten Public Offering of Common Stock and Warrants to Purchase Common Stock

SOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that it...